Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits

Ophthalmic Research

Volumn 29, Issue 1, 1997, Pages 1-5

  Hodges, Linda C ^a   Reggio, Patricia H ^b   Green, Keith ^c  

^a AGNES SCOTT COLLEGE   (United States)

^b KENNESAW STATE UNIVERSITY   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Aminoalkylindole; Cannabinoid; Intraocular pressure; Methanandamide; Rabbit

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030898360     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000267984     Document Type: Article

References (24)

1. Perez-Reyes M, Wagner D, Wall ME, Davis KH: Intravenous administration of cannabinoids and intraocular pressure; in Braude MC. Szara S (eds): The Pharmacology of Marihuana. New York. Raven Press, 1976. pp 829-832.
2. Green K, Bowman K: Effects of marihuana derivatives on aqueous humor dynamics in the rabbit; in Braude MC, Szara S (eds): The Pharmacology of Marihuana. New York. Raven Press. 1976. pp 803-813.
3. Razdan RK: Structure-activity relationships in cannabinoids. Pharmacol Rev 1986;38:75-149.
4. Gérard C, Mollereau C, Vassart G, Parmentier M: Nucleotide sequence of a human cannabinoid receptor cDNA. Nucleic Acids Res 1990; 18: 7142.
5. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
6. Gérard C, Mollereau C, Vassart G, Parmentier M: Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Bio-chemJ 1991;279:129-134.
7. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
8. Lynn Ab, Herkenham M: Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol ExpTher 1994;268:1612-1623.
9. D‘Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC, Chippari SM, Gre-go JD, Kullnig RK, Daley GT: Con-formationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)in-dole agonists of the cannabinoid receptor. J Med Chent 1992,35:124-135.
10. Ward SJ, Baizman E, Bell M, Childers S, D'Ambra T, Eissenstat M, Estep K, Haycock D, Howlett A, Lut-tinger D, Miller M, Pacheco M: Aminoalkylindoles (AAls): A new route to the cannabinoid receptor? Proceedings of the 1990 Committee on Problems of Drug Dependence. NIDA Monogr 1991;105:425-426.
11. Jansen EM, Haycock DA, Ward SJ, Scybold VS: Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res 1992;575:93-102.
12. 9-tctrahydro-cannabinol. J Pharmacol Exp Ther 1992;263:1118-1126.
13. Dcvanc WA, Hanus L, Brcuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etin-ger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
14. Fride E, Mechoulam R: Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993;231:313-314.
15. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR: The pharmacological activity of anandamide, a putative endogenous cannabinoid in mice. J Pharmacol ExpTher 1994:270:219-227.
16. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Ma-kriyannis A: (R)-Methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994;37: 1889-1893.
17. Pate DW, Jarvinen K, Urtti A, Jar-ho P. Jarvinen T: Arachidonyletha-nolamidc decreases intraocular pressure in normotensive rabbits. CurrEyeRes 1995:14:791-797.
18. Deutsch HM, Green K, Zalkow LH: Water-soluble high molecular weight components from plants with potent intraocular pressure lowering activity. Curr Eye Res 1987,6:949-950.
19. Green K, Symonds CM, Oliver NW, Elijah RD: Intraocular pressure following systemic administration of cannabinoids. Curr Eye Res 1982/3: 4:247-253.
20. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, dc Costa BR, Rice KC: Cannabinoid receptor localization in brain. Proc Natl Acad Sei USA 1990:87:1932-1936.
21. Mechoulam R, Feigenbaum JJ, Under N, Segal M, Jarbe TUC, Hil-tunen AJ, Consroe P: Enantiomeric cannabinoids: Stereospecificity of psychotropic activity. Experientia 1988;44:762-764.
22. 8-tetrahydro-cannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology 1990;29:161-165.
23. Beilin M, Aviv H, Friedman D, Vered M, Belkin M, Neumann R, Amsclen S, Schwartz J, Bar-Ilan A: HU211, a novel synthetic, non-psychotropic cannabinoid with ocular hypotensive activity. Invest Ophthalmol Vis Sei 1993;34(suppl): 1113.
24. Liu JHK, Dacus AC: Central nervous system and peripheral mechanism in ocular hypotensive effect of cannabinoids. Arch Ophthalmol 1987;105:245-248.